echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New ranking of top 10 pharmaceutical companies! H1 has a total revenue of nearly US $200 billion, with a total of 3587 clinical studies focusing on tumors

    New ranking of top 10 pharmaceutical companies! H1 has a total revenue of nearly US $200 billion, with a total of 3587 clinical studies focusing on tumors

    • Last Update: 2019-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Drug research and development is a slow development process Those big pharmaceutical companies that have developed for hundreds of years have taken the first mover advantage in this field These giants control the world's most valuable drugs, the top team and the most powerful capital The cooperation and collision between giants affect the trend of the whole drug field, and the M & A cases of tens of billions of times make the top pharmaceutical companies attract enough attention Big pharmaceutical companies have released their scores of 2019h1, and the latest ten have been published In the first half of this year, what changes have quietly taken place in the pattern of pharmaceutical enterprises? Who made it to the top ten, and who left? When can xiumeile medicine King sit on the throne? What is keytruda's performance after being approved for indications in a row? How does China's volume purchasing affect the pattern of pharmaceutical enterprises in the world? How are these pharmaceutical giants planning for their future development? New list of top 10 pharmaceutical companies: Lilly left, and the new list of top 10 pharmaceutical companies on BMS 2019h1 changed slightly in the first half of 2019 In 2018, Lilly entered the top 10 with a revenue of US $24.556 billion After performance correction, the revenue of 2019h1 was only US $10.729 billion, even less than US $11.187 billion of AstraZeneca, falling out of the top 10 list BMS, on the other hand, replaced Lilly No 9 with $12.193 billion in revenue thanks to eliquis and opdivo At the same time, Pfizer still tops the list with revenue of US $24.661 billion, but the gap between the two has narrowed to less than US $400 million under the rapid growth trend of Roche in the first half of the year If Pfizer's performance continues to grow sluggishly in the second half of the year, Roche will have the opportunity to surpass Pfizer to the top of the pharmaceutical industry by the end of 2019 At the same time, with the rapid development of keytruda, MSD also exchanged positions with Johnson & Johnson In Pfizer's and Sanofi's annual reports, both mentioned the impact of domestic 4 + 7 volume procurement on its revenue Pfizer's main growth drivers in 2018 came from China and other emerging markets, with the Chinese market growing by more than 20% But in the first half of 2019, Pfizer's non patent and generic pharmaceutical business unit, Upjohn, saw a significant decline in performance The key reason is that the volume of procurement projects reduced Upjohn's business in China by 20% Sanofi warned in some of its drug pipelines that sales of Plavix and Aprovel / Avapro may decline in the second half of the year due to the promotion of China's volume purchase projects Compared with the growth rate of 2019h1, the R & D investment of top ten pharmaceutical companies is generally kept at 15-20% of revenue (Johnson & Johnson did not disclose the R & D investment of pharmaceutical business, so the data shows the proportion of total R & D investment) Interestingly, when we overlap the year-on-year growth rate and R & D investment of pharmaceutical companies, we find that there is a significant positive relationship between them New drug research and development is gradually moving towards decentralization, and a large number of start-up pharmaceutical companies are involved in this high threshold and high regulatory industry As a result, many large pharmaceutical companies are gradually reducing their R & D expenditure and acquiring new drug pipelines through acquisition However, in terms of the correlation between R & D investment and the development of pharmaceutical enterprises, maintaining the proportion of R & D investment of about 20% may be the key to the rapid growth of pharmaceutical enterprises Two M & A cases with more than 50 billion US dollars will reshape the pattern of pharmaceutical enterprises The top ten M & A cases of pharmaceutical enterprises in 2019h1 are undoubtedly the BMS acquisition of Xinji and the acquisition of Erjian by ebev in 2019h1 The two acquisitions are about the same amount, and the attitude of the secondary market seems to be basically the same On January 3, 2019, BMS announced that it would purchase new base pharmaceutical for us $74 billion BMS fell 14% to $45.12 from $52.43 A similar situation happened to Aberdeen On June 4, 2019, Alberto announced that it would acquire Elgin for us $63 billion Shares in Aberdeen plunged to $65.70 from $78.45 The decline was 16% If we compare it by revenue capability, SGP is certainly worth a lot more than Elgin New base pharmaceutical holds the world's second-largest drug, Revlimid, with a revenue of 8.4 billion US dollars and a net income of 3.1 billion US dollars in 2019h1, close to the volume of top 10 pharmaceutical companies Elgin has yet to report its second quarter results, with a net loss of $2.4 billion on its 2019q1 revenue of $3.6 billion The reason for aibowei's acquisition of aierjian may be that it hopes to discover "the next xiumeile" from aierjian's drug pipeline Erjian is one of the few large pharmaceutical companies that do not involve in the field of tumor At present, there are 68 clinical trials, 43 of which are in phase III / IV clinical stage Its main business is distributed in the fields of nervous diseases, digestive system diseases, ophthalmic diseases and other diseases The main indications concerned include macular edema, diabetic gastroparesis, migraine and other diseases with large number of patients and poor effect of the current treatment program Therefore, in the next few years, it is likely that Elgin will have a series of drugs on the market, and each drug has a huge market potential As long as one of the drugs is successful, Elgin will have a chance to reverse the decline That's why Albuquerque is paying attention to Erjian There are 13 drugs with sales volume of more than $2 billion, xiumeile is on the decline In 2019h1, xiumeile, a top 10 pharmaceutical company with sales volume of more than $2 billion, finally shows weakness in 2019h1, with sales volume of $9.32 billion, a decrease of $570 million compared with the same period in 2018, a year-on-year decrease of 5.84% Although Sumeria's half year sales of nearly $10 billion are still beyond the reach of other drugs, as we predicted at the beginning of the year, the decline in sales due to the expiration of patents in the European market has had a real impact on the overall performance of Aberdeen The performance of EBV in 2019H1 fell by 0.80% year on year, and Miller repair is undoubtedly the most important factor In the PD-1 market, the competition between keytruda and opdivo has always been a topic of great interest In the first half of 2018, opdivo still led by a small margin But in the frenzy of keytruda's expansion of indications, keytruda surpassed opdivo in sales for the first time at the end of 2018 The performance of 2019h1 completely declared keytruda's victory in this confrontation Keytruda 2019h1 sales reached US $4.9 billion, up 56.60% year on year Although odivo has also maintained growth and reached a new high of $3.62 billion, it has been far behind keytruda What's more, of the 638 clinical trials that MSD is working on, 414 are related to keytruda As the second best-selling drug in 2018, Revlimid of new base pharmaceutical reached a new peak of $5.31 billion in sales in 2019h1, up 13.3% year on year Revlimid is the next king of Medicine's most powerful competitor in the context of Sumeria's declining sales But keytruda, catching up, is closing the gap between itself and Revlimid to $400 million in 2019h1 with its rapid growth If keytruda can maintain such a strong momentum in the second half of the year, it will have the opportunity to compete with Revlimid in 2019 Although opdivo did not win the competition with keytruda, the sales volume of US $3.62 billion in 2019h1 was enough for opdivo to rank in the top five single drug sales of the top ten pharmaceutical companies In addition to opdivo, eliquis, another star drug of BMS, also performed well in the first half of the year, with a total sales volume of $3.97 billion, an increase of $810 million compared with 2018h1 These two drugs contributed 62% of the sales volume of 2019h1 to BMS, which helped BMS to be included in the list of top ten pharmaceutical companies 3587 clinical trials and 10 pharmaceutical companies besieged the tumor artery network On July 30, 2019, they counted 13418 drug clinical trials on clinical trails that were sponsored by businesses and were in an active state They sorted out the indications, stages, sponsors, current status and other information of all clinical trials one by one, and finally integrated them into a global drug clinical trial database In order to show the layout direction of the top ten pharmaceutical enterprises more clearly, we screened 3587 clinical trials directly participated in by the top ten pharmaceutical enterprises in 2019h1 from the clinical database, and made an overall analysis on the pipeline reserve richness, the layout of indication fields and the layout of hot indications of each pharmaceutical enterprise As of July 30, 2019, the number of clinical trials in research and the proportion of phase III / IV clinical trials of the top ten pharmaceutical companies were as shown in the figure above The clinical trial shows the reserve of drug pipeline in pharmaceutical companies There are more than 500 registered clinical trials of MSD, BMS and Novartis, of which 638 are clinical trials and 190 are phase III / IV clinical trials Aberdeen has only 195 clinical trials under research, and is the only one of the top 10 pharmaceutical companies with no more than 200 The lack of follow-up drug pipeline may also be one of the key reasons for abwi's acquisition of Erjian The top ten pharmaceutical companies are divided into two groups in terms of the distribution of indications in clinical trials One group includes Merck, Roche and BMS Most of the sales of these three pharmaceutical companies are basically provided by several drugs in the head In terms of clinical pipeline layout, these three pharmaceutical companies also focus on their own key drug pipelines The advantage of this strategy is that long-term R & D in the same field can accelerate the accumulation of R & D experience and make the subsequent R & D process more smooth In addition, the successful single drug has a very strong explosive force For example, MSD has experienced explosive growth in recent two years with the strength of keytruda But the disadvantage of this strategy is obvious, that is, it is easy to be affected by the patent cliff The distribution of indications of other pharmaceutical companies is relatively average Pfizer has a certain layout in almost all disease areas As the third largest pharmaceutical company, Novartis has not even sold any medicine with a sales volume of more than $2 billion in 2019h1 Such a development strategy is more stable, which can ensure the long-term smooth growth of its own performance, not suddenly impacted by the market of other drugs, and the risk of patent cliff is also small But the disadvantage is the lack of explosive power, which may lead to slow progress in some areas due to decentralized investment Tumor is a disease area that ten pharmaceutical companies are focusing on In particular, MSD and BMS have made great efforts to expand the indications of keytruda and opdivo The second most concerned area is infectious diseases Especially for HIV, HCV, pneumococcus and other diseases where there is no clinical solution or the solution is not good enough, major pharmaceutical companies are trying to layout The hot indications in the clinical trials of the top ten pharmaceutical companies are distributed in specific indications, and the five high indications are all tumors The diseases that big pharmaceutical companies pay attention to are basically tumors and chronic diseases The former is just needed by patients, while the latter has a good market prospect Rare diseases are less in the clinical trials of large pharmaceutical companies as a whole, "serious diseases" are still the core of their attention Breast cancer and lung cancer are the two most concerned indications New progress has been made in the field of breast cancer in 2019 Roche's tecentriq was approved by FDA for triple negative breast cancer treatment in March 2019, becoming the first immunotherapy for triple negative breast cancer treatment Novartis' ibrance was approved in April 2019 for the treatment of male breast cancer In addition, MSD announced K at the end of July
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.